Major Government Initiatives to Combat Sickle Cell Disease
Recognizing the severe public health impact of Sickle Cell Disease (SCD), particularly among tribal populations, the government has launched several targeted initiatives to prevent, manage, and eventually eliminate the disorder.
National Sickle Cell Anaemia Elimination Mission
Announced in the Union Budget 2023, this is the flagship public health program addressing the challenges posed by SCD.
- Vision and Target: The primary goal is to completely eliminate SCD as a public health issue in India by the year 2047.
- Beneficiaries: The mission aims to cover over 7 crore individuals within its first three years (2023 to 2026). The primary focus is on children and adolescents (from birth to 18 years) for early intervention, and adults (up to 40 years) for broader screening.
- Progress: Over 3.37 crore individuals have been successfully screened under the program, with more than 3.22 crore confirmed negative for the disease.
Four Main Pillars of the Mission
1. Screening
- Mass Testing: Universal screening of all newborns and pregnant women in affected regions using rapid diagnostic tests.
- Genetic Status Card: Individuals who test positive are issued a permanent genetic status card. This card is crucial for accessing appropriate healthcare and making informed reproductive and marriage decisions.
2.Prevention
- Genetic Counselling: Couples identified as carriers receive extensive counselling regarding the probability of having a child with the active disease.
- Prenatal Diagnosis: Pregnant women are offered prenatal testing to determine if the foetus has the severe form of the disease, providing them with medical options, including termination of pregnancy.
3. Treatment
- Free Medical Care: Patients with active sickle cell disease receive free and regular medical management. This includes blood transfusions, pain management, antibiotics, and Hydroxyurea therapy.
- National Registry: All diagnosed patients are enrolled in a national digital registry to constantly monitor their health outcomes and treatment progress.
4.Research
- Scientific Innovation: The mission actively funds and supports research into developing new drugs and permanent cures tailored for the Indian population, such as advanced gene therapy and stem cell (bone marrow) therapy.
Challenges in Implementation
- Widespread lack of awareness and social stigma associated with genetic diseases.
- Resource and logistical constraints in ensuring safe blood supply and specialized medical staff in remote tribal areas.
- Complex ethical and legal sensitivities regarding genetic testing and prenatal diagnosis.
National Health Mission (NHM) 2013
The NHM provides a broad administrative framework for disease prevention and management, with a dedicated focus on hereditary anomalies.
- Awareness and Detection: Specific programs within the NHM are designed to raise public awareness, facilitate early detection, and ensure timely medical intervention for sickle cell patients.
- Essential Medicines: The NHM ensures the availability of crucial life-saving drugs by including medications like Hydroxyurea (the primary drug used to manage SCD pain crises) in its Essential Medicines List.
Regulatory Guidelines and Research
To promote advanced medical research and find a permanent genetic cure, the government has established strict scientific frameworks.
1. National Guidelines for Stem Cell Research (2017):
- These guidelines strictly restrict the commercialization of stem cell therapies, limiting them to clinical trials.
- However, a specific medical exception is made for Bone Marrow Transplantation (BMT) for SCD, recognizing it as a standard treatment.
- Gene editing on stem cells is currently permitted only for laboratory (in-vitro) studies.
Gene Therapy Guidelines (2019):
- The National Guidelines for Gene Therapy Product Development and Clinical Trials provide a safe, regulated framework for developing genetic cures for inherited disorders.
- Under this framework, India has formally approved a five-year scientific project to develop advanced CRISPR (gene-editing) techniques specifically tailored for treating sickle cell anaemia.
